34 Demographics, Clinical Characteristics, and Treatment Patterns for Patients With BRCA-Mutated, HER2-Negative Early-Stage Breast Cancer: a CancerLinQ Real-World US Study

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 46

Stella Mokiou, PhD1; Richard W. DeClue, PhD, MPH2; Santosh Gautam, PhD2; Lisa Herms, PhD2; Miao Jiang, PhD3; Ping Sun, PhD4; Susan McCutcheon, PhD4; Vered Stearns, MD5; Maria Raquel Nunes, MD5

1AstraZeneca, Cambridge, England, UK; stella.mokiou@astrazeneca.com

2ConcertAI, Memphis, TN

3AstraZeneca, Gaithersburg, MD

4AstraZeneca, Cambridge, England, UK

5Johns Hopkins School of Medicine, Baltimore, MD

Background

Despite several reports of the real-world clinical characteristics and treatment patterns of patients with early-stage breast cancer (ESBC), specific information is lacking for patients with BRCA-mutated (BRCAm) ESBC. We conducted a retrospective study focusing on patients with BRCAm, HER2-negative (HER2–) ESBC, including both hormone receptor–positive (HR+) and –negative (HR–), as well as triple-negative breast cancer (TNBC).

Materials and Methods

We identified patients ( 18 years) from the CancerLinQ electronic medical record database, diagnosed with stage I through IIIA HER2– breast cancer between January 1, 2014 and January 1, 2019. BRCA mutation status was determined based on available test results: BRCAm, wild-type BRCA (BRCAwt), or unknown/untested (BRCAunk). Patient characteristics and treatments were summarized by BRCA status for HR+ and TNBC cohorts. AstraZeneca– ConcertAI Confidential and Proprietary Information Version 3.0 Page 2 of 2 January 13, 2021.

Results

In total, 4566 patients (BRCAm = 41; BRCAwt = 492; BRCAunk = 4033) were identified in the HR+ cohort and 703 (BRCAm = 20; BRCAwt = 135; BRCAunk = 548) in the TNBC cohort. Patients with BRCAm were younger and received surgery plus adjuvant therapy more frequently, whereas fewer patients received radiation versus BRCAwt and BRCAunk overall. Among the HR+ cohort, 68.3% of patients with BRCAm were stage II or IIIA at diagnosis (vs 46.5% BRCAwt and 40.4% BRCAunk), and 53.7% had a poorly differentiated grade 3 tumor (vs 19.9% BRCAwt and 16.3% BRCAunk). Clinical characteristics were similar

by BRCA status for the TNBC cohort. Among patients receiving neoadjuvant treatment (n = 282 [6.2%] HR+; n = 206 [29.3%] TNBC), doxorubicin plus cyclophosphamide and either paclitaxel or docetaxel (AC-T regimen) was the most common therapy (42.9%, HR+; 50.0%, TNBC). Among patients with HR+ disease, 66.7% of those with BRCAm disease received AC-T alone; among those with TNBC, 71.4% patients with BRCAm disease received AC-T alone. Among patients with HR+ disease receiving adjuvant treatment (n = 2641; 57.8%), 63.4% received hormonal therapy and 9.6% received both AC-T and hormonal therapy. Among those with HR+ and BRCAm, 31.0% received adjuvant AC-T/hormonal therapy. Among patients with TNBC receiving adjuvant treatment (n = 370; 52.6%), 31.6% received AC-T alone (similar across BRCA groups), with 92.3% BRCAm receiving chemotherapy.

Conclusions

This study provides insight into characteristics and treatment patterns of patients with BRCAm ESBC in real-world oncology settings in the United States. Consistent with prior studies, patients with BRCAm were diagnosed at a younger age, and for the HR+ cohort, with higher tumor grade and at a later disease stage. The use of chemotherapy, in both neoadjuvant and adjuvant settings, was more frequent for patients with BRCAm.

Sponsor: AstraZeneca

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content